Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 4
1982 4
1983 2
1984 2
1985 3
1986 3
1987 10
1988 5
1989 12
1990 31
1991 26
1992 25
1993 35
1994 37
1995 41
1996 37
1997 58
1998 82
1999 78
2000 105
2001 112
2002 142
2003 195
2004 272
2005 327
2006 357
2007 431
2008 559
2009 614
2010 759
2011 899
2012 1058
2013 1134
2014 1409
2015 1515
2016 1522
2017 1644
2018 1872
2019 2088
2020 2544
2021 2893
2022 3383
2023 3281
2024 3778
2025 4399
2026 2640

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36,261 results

Results by year

Filters applied: . Clear all
Page 1
Anti-asthma drug montelukast induces autistic behaviors via disrupting neuronal retinoic acid signaling.
Hao ZJ, Wu QH, Li YL, Guo ZM, Li ZW, Wang G, Meng M, Yuan SL, Wufuer Y, Zhang MH, Chen J, Yang T, Chen MX, Zhu J, Qi-Hang W, Li Q, Yu SH, Lu M, Xiong HY, Feng YR, Dong MQ, Xu JH, Xu JL, Chen L, Yang HT, Miao JK, Zhu H, Yang B, Zhao HY, Shi XM, Bian S, Li TY, Hu RG. Hao ZJ, et al. Among authors: zhu h. Signal Transduct Target Ther. 2026 Jun 2;11(1):208. doi: 10.1038/s41392-026-02665-w. Signal Transduct Target Ther. 2026. PMID: 42230569 Free PMC article.
Lactate-Driven Restriction of Mitochondrial Permeability Transition Promotes Resistance to Chemo-Immunotherapy by Suppressing Tumor PANoptosis.
Zhong S, Chen W, Liu F, Zhou S, Yu B, Wang Y, Zhou X, Wang X, Liu D, Zhang Z, Wang X, Lalouly M, Li Y, Du Z, Yan T, Xiao Z, Zhou Z, Zhu H, Qian F, Zheng B, Fang L. Zhong S, et al. Among authors: zhu h. Adv Sci (Weinh). 2026 Jun 30:e76321. doi: 10.1002/advs.76321. Online ahead of print. Adv Sci (Weinh). 2026. PMID: 42378634 Free PMC article.
Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.
Takahashi N, Kim DW, Kim I, Du X, Lee SE, Hu Y, Kikushige Y, Jiang Q, Wang Y, Chen S, Zhu H, Goto T, Tomita A, Ichii M, Nakamae H, Liu L, Liu B, Malek K, Zhu T, Wu S, Wang J. Takahashi N, et al. Among authors: zhu h. Cancer Med. 2026 Jun;15(6):e72019. doi: 10.1002/cam4.72019. Cancer Med. 2026. PMID: 42339511 Free PMC article. Clinical Trial.
36,261 results
You have reached the last available page of results. Please see the User Guide for more information.